Inhibrx Future Growth

Future criteria checks 2/6

Inhibrx is forecast to grow earnings and revenue by 9.1% and 59.7% per annum respectively while EPS is expected to grow by 13.1% per annum.

Key information

9.1%

Earnings growth rate

13.1%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	59.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 May 2024

Recent future growth updates

Recent updates

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 05

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Earnings and Revenue Growth Forecasts

NasdaqGM:INBX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	122	-296	N/A	N/A	1
12/31/2025	2	-361	N/A	N/A	1
12/31/2024	N/A	-316	N/A	N/A	2
3/31/2024	2	-271	-222	-216	N/A
12/31/2023	2	-241	-198	-193	N/A
9/30/2023	0	-189	-169	-167	N/A
6/30/2023	1	-172	-144	-144	N/A
3/31/2023	1	-163	-129	-128	N/A
12/31/2022	2	-145	-116	-115	N/A
9/30/2022	5	-125	-108	-107	N/A
6/30/2022	7	-111	-91	-90	N/A
3/31/2022	7	-94	-87	-86	N/A
12/31/2021	7	-82	-81	-80	N/A
9/30/2021	7	-78	-74	-73	N/A
6/30/2021	11	-78	-75	-73	N/A
3/31/2021	13	-75	-64	-62	N/A
12/31/2020	13	-76	-49	-48	N/A
9/30/2020	10	-75	-46	-45	N/A
6/30/2020	6	-74	-33	-31	N/A
3/31/2020	6	-68	-36	-34	N/A
12/31/2019	13	-51	-34	-32	N/A
9/30/2019	15	-40	-29	-27	N/A
6/30/2019	15	-30	-29	-27	N/A
3/31/2019	14	-26	-28	-27	N/A
12/31/2018	9	-31	-25	-23	N/A
9/30/2018	7	-35	-24	-23	N/A
12/31/2017	8	-19	N/A	-19	N/A
12/31/2016	7	-8	N/A	-18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INBX's revenue (59.7% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: INBX's revenue (59.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INBX's Return on Equity is forecast to be high in 3 years time

Inhibrx Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target decreased by 20% to US$35.50

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

Consensus revenue estimates increase by 26%

Consensus revenue estimates fall by 85%

Recent updates

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020)

Price target increased to US$42.60

Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020)

Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts